M
Michael Paulussen
Researcher at Witten/Herdecke University
Publications - 91
Citations - 5544
Michael Paulussen is an academic researcher from Witten/Herdecke University. The author has contributed to research in topics: Sarcoma & Ewing's sarcoma. The author has an hindex of 29, co-authored 86 publications receiving 4751 citations. Previous affiliations of Michael Paulussen include University of Paris-Sud & University College Hospital.
Papers
More filters
Journal ArticleDOI
Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group
Simon Cotterill,S. Ahrens,Michael Paulussen,Heribert Jürgens,P. A. Voûte,H. Gadner,Alan W. Craft +6 more
TL;DR: Survival and RFS improved over the period and radiotherapy or amputation were more common in the period before 1986, whereas endoprosthetic surgery was widely used in the later period.
Journal ArticleDOI
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Nathalie Gaspar,Douglas S. Hawkins,Uta Dirksen,Ian Lewis,Stefano Ferrari,Marie-Cécile Le Deley,Marie-Cécile Le Deley,Heinrich Kovar,R Grimer,Jeremy Whelan,Jeremy Whelan,Line Claude,Olivier Delattre,Michael Paulussen,Piero Picci,Kirsten Sundby Hall,Hendrik van den Berg,Ruth Ladenstein,Jean Michon,Lars Hjorth,Ian Judson,Ian Judson,Roberto Luksch,Mark L. Bernstein,Perrine Marec-Berard,Bernadette Brennan,Alan W. Craft,Richard B. Womer,Heribert Juergens,Odile Oberlin +29 more
TL;DR: The many insights into the biology of the EWS-FLI1 protein in the initiation and progression of ES remain to be translated into novel therapeutic strategies and current options and future approaches will be discussed.
Journal ArticleDOI
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial
Ruth Ladenstein,Ulrike Pötschger,Marie-Cécile Le Deley,Jeremy Whelan,Michael Paulussen,Odile Oberlin,Henk van den Berg,Uta Dirksen,Lars Hjorth,Jean Michon,Ian Lewis,Alan W. Craft,Heribert Jürgens +12 more
TL;DR: PDMES patients may survive with intensive multimodal therapy with a dose-intense treatment concept and age, tumor volume, and extent of metastatic spread are relevant risk factors.
Journal ArticleDOI
Ewing’s Sarcoma Family of Tumors: Current Management
Mark L. Bernstein,Heinrich Kovar,Michael Paulussen,R. L. Randall,Andreas Schuck,Lisa A. Teot,Herbert Juergens +6 more
TL;DR: Patients with initially metastatic disease fare less well, with about one quarter surviving, and new approaches include anti-angiogenic therapy, particularly since vascular endothelial growth factor is an apparent downstream target of the ews-fli1 oncogene.
Journal ArticleDOI
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial
Christine Juergens,Claire Weston,Ian Lewis,Jeremy Whelan,Michael Paulussen,Odile Oberlin,Jean Michon,Andreas Zoubek,Herbert Juergens,Alan W. Craft +9 more
TL;DR: The EUROpean Ewing tumour Working Initiative of National Groups 1999 protocol prescribes six courses of vincristine, ifosfamide, doxorubicin, and etoposide as intensive induction chemotherapy for Ewing tumors (ET).